The UK Competition Appeal Tribunal finds a pharmaceutical company guilty of margin squeeze but rejects the OFT’s evidence on bundling (Genzyme)

Genzyme Limited ("Genzyme") is a pharmaceutical company which produces Cerezyme - the main drug for the treatment of Gaucher disease. The drug is taken by approximately 190 patients in the United Kingdom and is usually administered at home with the assistance of trained medical staff. Between 1998 and 2001, Healthcare at Home Limited ("HH"), a home healthcare company, had an exclusive contract with Genzyme for the delivery and home care associated with the administration of Cerezyme to Gaucher patients. In May 2001, Genzyme established its own in-house delivery and home care services and bundled it with the supply of the drug. Subsequently, Genzyme terminated the contract with HH and was only prepared to continue to supply the latter at its new bundled price, which was also the price

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

 

PDF Version

Author

Quotation

Dominik Piotrowski, The UK Competition Appeal Tribunal finds a pharmaceutical company guilty of margin squeeze but rejects the OFT’s evidence on bundling (Genzyme), 11 March 2004, e-Competitions Bulletin March 2004, Art. N° 21099

Visites 1397

All issues

  • Latest News issue 
  • All News issues
  • Latest Special issue 
  • All Special issues